Raining on the parade even more, Pfizer just reported some good news that seems to confirm the presence of some internal ...

Robert Burns, an analyst from H.C. Wainwright, reiterated the Buy rating on BioNTech SE (BNTX – Research Report). The associated price ...

The company launched a major cost-cutting program and made a significant acquisition, buying cancer specialist Seagen for US$43-billion, a move which Pfizer expects to boost revenue and profits.

Despite the performance, the company expects to be at the lower end of its revenue guidance window for the year of between €2 ...

On Oct. 29, Pfizer PFE announced third-quarter results, beating estimates for earnings as well as sales. Revenues rose 32% on ...

The firm updated estimates following Pfizer’s Comirnaty results and vaccine script trends for Comirnaty, Spikevax, and mResvia. Published first on TheFly – the ultimate source for real-time, ...

tick-borne encephalitis COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands Biosimilars for chronic immune and inflammatory diseases under the ...

The election results could spark market turbulence Raising cash makes sense after a 2-year market rally Sit back and let ...

Besides Sanofi deal for nuvaxovid, Novavax has few opportunities to generate additional revenue, which likely means its stock ...

Q3 2024 Earnings Conference Call October 29, 2024 10:00 AM ETCompany ParticipantsFrancesca DeMartino - Chief Investor ...

(Reuters) -Pfizer CEO Albert Bourla, under pressure from activist hedge fund Starboard Value, made his case to Wall Street on Tuesday that the drugmaker's turnaround is succeeding after it reported a ...

Unlike at the height of the pandemic, oral antiviral therapy Paxlovid is Pfizer's strongest COVID-19 product now instead of its Comirnaty vaccine. In the third quarter of 2024, Paxlovid raked in ...